A Runa, Mu Rigenjiya, Wu Qizhu, Ga Latai, Bai Long, A Rigatai, Bao Lidao, Si Lengge, A Gula
Mongolian Traditional Therapy Teaching and Research Section, Mongolian Medicine School, Inner Mongolian Medical University Hohhot, Inner Mongolia, China.
Mongolian Medical Orthopedics Teaching and Research Section, Mongolian Medicine School, Inner Mongolian Medical University Hohhot, Inner Mongolia, China.
Am J Transl Res. 2023 Apr 15;15(4):2481-2497. eCollection 2023.
The object of this paper was to evaluate the clinical efficacy and safety of Mongolian medicine in the treatment of osteoarthritis (OA). This was completed by offering evidence to provide a clinical basis for the treatment of OA. We explored the mechanism of the sticking application of Mongolian medicine.
A total of 123 patients with OA diagnosed in the Affiliated Hospital of Inner Mongolia Medical University from January 2017 to December 2017 were enrolled. The clinical data of the patients were retrospectively analyzed. Patients were divided into three groups according to the medication they were using at the time: The strapping group, the glucosamine hydrochloride group, and the Mongolian medicine group, with 41 patients in each group. The treatment indicators of the included patients 2 weeks after the treatment and 4 weeks after the treatment were fully recorded in our hospital. The levels of CGRP, TNF-α, MMP-3, VEGF, and IL-10 before and after treatment were measured by ELISA. The auxiliary diagnostic index was X-ray film.
Compared with the control group, the Mongolian medicine group improved the symptoms of pain, swelling, limited movement, and daily life quality of patients to different degrees. There was a significant decrease in the VAS score at each time point of the Mongolian medicine group (P < 0.05). tThe scores of bodily pain in SF-36 QOL were significantly higher in the Mongolian medicine group at different time points (P < 0.05). After treatment, the levels of MMP-3, TNF-α, VEGF, and CGRP in the Mongolian medicine group were significantly lower than those before the treatment (P < 0.05).
Mongolian medicine can inhibit the expression of MMP-3, TNF-α, VEGF, and CGRP in serum, and up-regulate the trend of IL-10, alleviating the inflammatory reaction. It has a good curative effect in the treatment of OA patients. It is better than western medicine in pain, swelling, and improving bone and joint function index.
本文旨在评估蒙药治疗骨关节炎（OA）的临床疗效及安全性，通过提供证据为OA的治疗提供临床依据，探索蒙药贴敷的作用机制。
选取2017年1月至2017年12月在内蒙古医科大学附属医院确诊的123例OA患者，对患者的临床资料进行回顾性分析。根据患者当时使用的药物将其分为三组：贴剂组、盐酸氨基葡萄糖组和蒙药组，每组41例。在我院详细记录纳入患者治疗后2周和4周的治疗指标。采用酶联免疫吸附测定法（ELISA）检测治疗前后降钙素基因相关肽（CGRP）、肿瘤坏死因子-α（TNF-α）、基质金属蛋白酶-3（MMP-3）、血管内皮生长因子（VEGF）和白细胞介素-10（IL-10）的水平。辅助诊断指标为X线片。
与对照组相比，蒙药组不同程度地改善了患者的疼痛、肿胀、活动受限及日常生活质量症状。蒙药组各时间点视觉模拟评分（VAS）均显著降低（P<0.05）。蒙药组在不同时间点的简明健康状况调查量表（SF-36）生活质量躯体疼痛评分显著更高（P<0.05）。治疗后，蒙药组MMP-3、TNF-α、VEGF和CGRP水平显著低于治疗前（P<0.05）。
蒙药可抑制血清中MMP-3、TNF-α、VEGF和CGRP的表达，上调IL-10的趋势，减轻炎症反应。对OA患者具有良好的治疗效果，在疼痛、肿胀及改善骨关节功能指标方面优于西药。
